DDInter557 DDInter785
A 9,10alpha-dihydro derivative of [ergotamine]. Dihydroergotamine is used as an abortive therapy for migraines. Its use has largely been supplanted by triptans in current therapy due to the class's greater selectivity and more favourable side effect profile. Recent improvements have been made in the design of intranasal delivery devices allowing for greater delivery of dihydroergotamine solution to the vasculature-rich upper nasal cavity. The recently approved Precision Olfactory Delivery technology developed by Impel Neuropharma technology has correlated with an increase of 3-fold in Cmax and 4-fold in AUC despite the solution formulated at 75% of the strength of the existing intranasal product.
Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA . Recently, fostamatinib has been identified as a potential therapeutic for controlling acute respiratory distress syndrome (ARDS) in patients with severe COVID-19 through its ability to modulate the SYK kinase.[A235008, A235013, A235018]
Dihydroergotamine {u} (Compound) resembles {v} (Compound) Ergotamine
Ergotamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fostamatinib
Dihydroergotamine {u} (Compound) resembles {v} (Compound) Ergotamine
Ergotamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Aprepitant
Aprepitant {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fostamatinib
Dihydroergotamine {u} (Compound) resembles {v} (Compound) Ergoloid mesylate
Ergoloid mesylate {u} (Compound) resembles {v} (Compound) Bromocriptine
Bromocriptine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fostamatinib
Dihydroergotamine {u} (Compound) resembles {v} (Compound) Ergotamine
Ergotamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pazopanib
Pazopanib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fostamatinib
Dihydroergotamine {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Dactinomycin
Dactinomycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fostamatinib
Dihydroergotamine {u} (Compound) resembles {v} (Compound) Bromocriptine
Bromocriptine {u} (Compound) resembles {v} (Compound) Ergotamine
Ergotamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fostamatinib
Dihydroergotamine {u} (Compound) binds {v} (Gene) HTR6
HTR6 {u} (Gene) is bound by {v} (Compound) Clozapine
Clozapine {u} may lead to a major life threatening interaction when taken with {v} Fostamatinib
Dihydroergotamine {u} (Compound) resembles {v} (Compound) Bromocriptine
Bromocriptine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Lorlatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fostamatinib
Dihydroergotamine {u} (Compound) resembles {v} (Compound) Ergotamine
Ergotamine {u} may lead to a major life threatening interaction when taken with {v} Sibutramine
Sibutramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fostamatinib
Dihydroergotamine {u} (Compound) palliates {v} (Disease) migraine
migraine {u} (Disease) is treated by {v} (Compound) Verapamil
Verapamil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fostamatinib
Dihydroergotamine (Compound) resembles Ergotamine (Compound) and Ergotamine may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Dihydroergotamine (Compound) resembles Ergotamine (Compound) and Ergotamine may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Dihydroergotamine (Compound) resembles Ergoloid mesylate (Compound) and Ergoloid mesylate (Compound) resembles Bromocriptine (Compound) and Bromocriptine may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Dihydroergotamine (Compound) resembles Ergotamine (Compound) and Ergotamine may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib and Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Dihydroergotamine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Dactinomycin (Compound) and Dactinomycin may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Dihydroergotamine (Compound) resembles Bromocriptine (Compound) and Bromocriptine (Compound) resembles Ergotamine (Compound) and Ergotamine may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Dihydroergotamine (Compound) binds HTR6 (Gene) and HTR6 (Gene) is bound by Clozapine (Compound) and Clozapine may lead to a major life threatening interaction when taken with Fostamatinib
Dihydroergotamine (Compound) resembles Bromocriptine (Compound) and Bromocriptine may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Dihydroergotamine (Compound) resembles Ergotamine (Compound) and Ergotamine may lead to a major life threatening interaction when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Dihydroergotamine (Compound) palliates migraine (Disease) and migraine (Disease) is treated by Verapamil (Compound) and Verapamil may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib